After years of research and development, we have a balanced and diversified product pipeline with a strategic focus on major cancers and other AR related diseases.

Note: 1.In addition, IND for basal-cell carcinoma indication has been cleared by FDA in the U.S.; 2. Will conduct phase II clinical trial directly due to good safety, and the protocol is under preparation

      mCRPC = metastatic castration-resistant prostate cancer

      HCC =hepatocellular carcinoma

      GC = gastric carcinoma

      GEJ = gastroesophageal junction

      UC = urothelial carcinoma

      ESCC = esophageal squamous cell carcinoma

      PROTAC = proteolysis targeting chimera